USC scientists create a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable
USC researchers have developed a polio vaccine that doesn’t require refrigeration, meaning it could someday be used all over the world to deliver the final blow to this longtime foe.
The vaccine, which was freeze-dried into a powder, kept at room temperature for four weeks and then rehydrated, offered full protection against the polio virus when tested in mice.
Stabilization is not rocket science, so most academics don’t pay much attention to this field.
“Stabilization is not rocket science, so most academics don’t pay much attention to this field,” said the study’s first author, Woo-Jin Shin, a fellow in the lab of Jae Jung, chair of the Department of Molecular Microbiology and Immunology at the Keck School of Medicine of USC. “However, no matter how wonderful a drug or vaccine is, if it isn’t stable enough to be transported, it doesn’t do anyone much good.”
The study appears in the Nov. 27 issue of the journal mBio.
Polio is on the brink of complete eradication, with just 22 reported cases worldwide in 2017. The highly infectious disease, which causes lifelong paralysis and disability mostly in young children, is a fading memory in many places. Yet in countries where vaccination rates are spotty, young children are at risk.
The biggest hitch to complete eradication has been creating a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable. Recent polio cases have been reported in Nigeria, Papua New Guinea, Syria and Pakistan.
Other freeze-dried vaccines
In the United States, the polio epidemic reached its height in the 1950s. In 1957, mass immunization brought the annual number of cases down from 58,000 to 5,600. Since 1979, no cases of polio have originated in the United States.
By removing moisture through freeze-drying, researchers have created temperature-stable vaccines for measles, typhoid and meningococcal disease. But scientists haven’t been able to make a polio vaccine that retains potency through freeze-drying and rehydration.
Shin and his colleagues used two lab techniques — liquid chromatography and high-throughput screening — that allowed them to analyze a high volume of ingredients and formulations until they found one that worked.
Jung’s hope is that a foundation or company will take over the project to pay for human studies and bring the injectable vaccine onto the market.
In addition to Shin, the study’s authors are Daiki Hara and Jae Jung of the Keck School of Medicine, and Francisca Gbormittah, Hana Chang and Byeong S. Chang of Integrity Bio, a company that specializes in biologics — medicines made from substances found in living things.
Back story: During dinner three years ago, Jung and his college buddy Chang, CEO of Integrity Bio, decided to bring together Jung’s virology expertise with Chang’s expertise in stabilization. Chang paid Shin’s salary, and Jung provided supplies.
“He and I decided to do this as we are getting old and we need to directly contribute to human health and life,” Jung said. “Creative ideas always start with food and drinks.”
The Latest on: Temperature-stable vaccine
via Google News
The Latest on: Temperature-stable vaccine
- FDA advisers to meet this week on Johnson & Johnson’s Covid-19 vaccineon February 24, 2021 at 10:57 am
The single-dose vaccine prevents hospitalizations and deaths, but has a lower efficacy against the illness than other vaccines.
- SARS-CoV-2 DNA vaccine tested in animal modelon February 21, 2021 at 8:16 pm
A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) ...
- How to tell if your food is spoiled after a power outageon February 17, 2021 at 2:04 pm
When the power goes out, try not to open doors to keep that temperature stable. Latest on power outages in Central Texas According to the Centers for Disease Control, with closed doors ...
- Los Angeles Times owner hosts video on vaccine science that blurs some business lineson February 17, 2021 at 7:00 am
The company is working to develop a “temperature-stable” vaccine in pill form. The videos starring Soon-Shiong have been posted on the Times website and on YouTube under the Times channel ...
- VIC Foundry, Inc. Receives NIH RADx Funding for Development of an At-home Molecular Diagnostic Test for COVID-19on February 16, 2021 at 7:53 am
The test cartridge is disposable and contains room temperature-stable dry reagents specific for two SARS-CoV-2 RNA targets and one internal control. Performing a test comprises the following ...
- UCT Covid-19 vaccine trial could solve growing problem of new variants of the viruson February 15, 2021 at 6:25 am
“We have begun clinical trials in the USA testing our room temperature stable oral version of the T-cell vaccine. Based on the encouraging results in the non-human primate studies in which these ...
- ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for ...on February 11, 2021 at 4:14 pm
One Vaccine, Two Trials ... due to additional genetic deletions. The hAd5 room temperature-stable oral capsules were developed in partnership with UK-based biotechnology company iosBio.
- ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal ...on February 10, 2021 at 9:00 pm
ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics ...
- Why Vaxart Stock Crashed Todayon February 3, 2021 at 5:38 pm
As a room-temperature stable oral vaccine, VXA-CoV2-1 would be easier to distribute, store, and administer than injectable vaccines with special cold storage requirements. But due to its apparent ...
via Bing News